Rebounding market share and strong pipeline may give Guidant hope
This article was originally published in Clinica
It has not been the best of weeks for Guidant. On the same day that it announced it was taking Johnson & Johnson to court, the company reported a 60% slash in profits for the third quarter.
You may also be interested in...
Biogen’s “recipe-driven qualification” knowledge management program standardizes data collection and reporting in the laboratory, with efficiency gains of 66%.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.